US Patent

US10449173 — Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions

Method of Use · Assigned to Allergan Sales LLC · Expires 2029-11-06 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for treating overactive bladders using non-occluded oxybutynin topical compositions.

USPTO Abstract

The invention relates to a method for treating overactive bladders and a device for storing and administering non-occluded oxybutynin topical compositions.

Drugs covered by this patent

oxybutynin-chloride (OXYBUTYNIN CHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2637`	—	oxybutynin-chloride

Patent Metadata

Patent number: US10449173
Jurisdiction: US
Classification: Method of Use
Expires: 2029-11-06
Drug substance claim: No
Drug product claim: Yes
Assignee: Allergan Sales LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.